Medical/Pharmaceuticals
Gracell Announces China MNPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
SHANGHAI and SUZHOU, China, April 3, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell & gene therapy company, is pleased to announce that China National Medical Products Administration (NMPA) has accepted Gracell's Investigational New Drug (IND) ap...
2020-04-03 22:00
159
VUNO offers a suite of AI solutions in response to the COVID-19 outbreak: VUNO Med(R)- LungQuant(TM) and VUNO Med(R)-Chest X-ray(TM): COVID-19
SEOUL, South Korea, April 3, 2020 /PRNewswire/ -- In the face of the COVID-19 pandemic raging around the globe,VUNO, a member company of the Born2Global Centre, has decided to move quickly by joining the global coalition to help address some critical issues facing the international healthcare com...
2020-04-03 20:30
193
SonoScape supports frontline battle against COVID-19 in Spain
MADRID, April 3, 2020 /PRNewswire/ -- SonoScape, as one of the leading providers of medical ultrasound and endoscopy solutions, has donated and delivered portable ultrasound systems to health care facilities where needed in Spain, pulling together to fight against COVID-19. COVID-19 has a foothol...
2020-04-03 16:50
443
Jolly Good and National Center for Cognitive Behavior Therapy and Research Enter Clinical Trial Collaboration for VR Therapeutics
TOKYO, April 2, 2020 /PRNewswire/ -- Jolly Good Inc. (hereinafter "Jolly Good") and the National Center for Cognitive Behavior Therapy and Research (hereinafter "NCCBTR") announced that they have entered into a clinical trial collaboration agreement directed toward the development of digital heal...
2020-04-02 16:00
310
Fosun Continues Joining Hand with Other Benevolent Enterprises in Donating Medical Supplies, to Hospitals in the U.S.
NEW YORK, April 1, 2020 /PRNewswire/ -- In response to the increasing numbers of global coronavirus pneumonia patients, Fosun's "Global Anti-Virus Relief Scheme" is continuing its efforts. Fosun Foundation donated the first batch of 18,000 pieces of masks to New York's NYU Langone Health and Mou...
2020-04-01 23:29
411
Drawing on Experience, United Imaging Prepares Transportable CTs for U.S. Deployment
HOUSTON, March 31, 2020 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, is preparing to deploy readily transportable CT scanners inthe United States to help in the fight against COVID-19, said a company spokesperson. United Imaging began wor...
2020-03-31 20:00
279
Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy
SAN DIEGO, March 31, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) announced today that its drug Silmitasertib (CX-4945) was determined to be a potential treatment forCOVID-19. To date, COVID-19, has infected over 700,000 people and killed over 34,000 people worldwide. COVID-19 is a ...
2020-03-31 19:00
390
China Pharma Holdings, Inc. Reports Fiscal Year 2019 Financial Results
HAIKOU CITY, China, March 31, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the ...
2020-03-31 18:30
2877
Fosun Pharma Announces 2019 Annual Results
SHANGHAI, March 31, 2020 /PRNewswire/ -- On March 30 2020, Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its annual results for the year 2019 ("the reporting period"). During the reporting period: ...
2020-03-31 17:51
3759
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%
HONGKONG, March 31, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2019 annual results, showing that the Company maintained steady growth, with core products continuously leading the market and more products being included into drug reimbursemen...
2020-03-31 12:29
3162
Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China
SUZHOU, China, March 30, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has established strategic partnership with Simcere and 3D Medicines (Beijing) Co....
2020-03-30 19:00
2512
Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development
SUZHOU, China and ROCKVILLE, MD, March 29, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for the...
2020-03-30 08:00
774
GenScript ProBio Congratulates XlifeSciences on the Start of TAEST16001 Early Phase Clinical Trial
NANJING, China, March 27, 2020 /PRNewswire/ -- Guangzhou XlifeSciences, a partner of GenScript ProBio (GenScript's CDMO segment) announced that the early phase clinical trial of TAEST16001 project has been started. GenScript ProBio extends congratulations on this. This clinical trial project is ...
2020-03-27 21:00
1419
Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)
SUZHOU, China, March 27, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has entered a clinical supply agreement with Pfizer Inc. ("Pfizer") to advance a ...
2020-03-27 19:00
3471
Luye Pharma Continues to Deliver Strong Growth in 2019
SHANGHAI, March 27, 2020 /PRNewswire/ -- Luye Pharma Group (02186.HK) reported its financial results for 2019 onMarch 27, 2020. According to the results, the company has achieved a total revenue ofRMB 6.358 billion, up 22.9% year-on-year. EBITDA wasRMB 2.488 billion, up 26.9% year-on-year; and n...
2020-03-27 16:44
3995
CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor
SUZHOU, China, March 27, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for avapritinib, a precision therapy being developed for the t...
2020-03-27 14:02
714
Fosun Pharma's Novel Coronavirus Nucleic Acid Detection Kit Receives Emergency Approval from China NMPA
SHANGHAI, March 26, 2020 /PRNewswire/ -- Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March"), a wholly-owned subsidiary ofShanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), has received emergency approval from the National Medica...
2020-03-26 22:27
4587
WuXi Biologics Achieved Remarkable Results in 2019
57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjusted Net Profit Up 60.3% to RMB1,205.0 Million Diluted EPS of RMB0.76 and Adjusted Diluted EPS of RMB0.91, Increasing 58.3% and 59.6% Backlog Increased 40.2% to US$5.1 Billion Milestone Payments Surg...
2020-03-26 21:32
4541
Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO
SUWON, South Korea, March 26, 2020 /PRNewswire/ -- Bio-Pharm Solutions Co., Ltd. has expanded its clinical pipelines from infantile spasms (IS) to status epilepticus (SE) and Alzheimer's disease. Based on the performance of its first pipeline, an infantile spasms drug, BIo-Pharm Solutions is c...
2020-03-26 21:00
503
Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID
SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership inEurope SEATTLE and BRISBANE, Australia, ...
2020-03-26 14:00
872
Week's Top Stories
Most Reposted
Fosun International Announces 2019 Annual Results
[Picked up by 141 media titles]
2020-03-31 18:14Suncity Group Holdings Limited Announces 2019 Unaudited Annual Results Update; HOIANA Phase 1 to Open in 2021, Preview in Summer 2020
[Picked up by 121 media titles]
2020-03-29 20:30Facebook Accelerator Singapore Introduces 14 Startups in Season 2
[Picked up by 112 media titles]
2020-03-31 10:02SIHL Reports Strong Results in Three Core Businesses
[Picked up by 109 media titles]
2020-03-31 21:21CTBC Bank focuses on asset digitalization - Seeks breakthrough from traditional mode of banking through partnership with Aegis
[Picked up by 108 media titles]
2020-03-30 17:28Most Read
Ping An Donates US$1.5 million of COVID-19 Medical Supplies to Indonesia
2020-03-28 00:57
6131
Fosun International Announces 2019 Annual Results
2020-03-31 18:14
5032
Exclusive Prediction: Pandemic Turning Point in European Countries and the U.S. is Expected to Arrive This Week / Early April
2020-03-31 00:01
4067
Ping An's Brand Value Breaks into World Top 10 for the First Time
2020-03-30 21:07
4011
SMIT Announces 2019 Annual Results
2020-03-30 10:54
3955